Figure 1.
VIPhyb-treatment enhanced the GvL activity (5 x 106 TCD BM and 0.5 x 106 splenocytes from WT or VIP-KO donors)

VIPhyb-treatment enhanced the GvL activity (5 x 106 TCD BM and 0.5 x 106 splenocytes from WT or VIP-KO donors)

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal